Invivyd Reports Ongoing Neutralizing Effect Of PEMGARDA Against Dominant SARS-CoV-2 Variants KP.3.1.1 And LB.1
Portfolio Pulse from Benzinga Newsdesk
Invivyd reports that their product PEMGARDA™ (pemivibart) continues to show neutralizing effects against dominant SARS-CoV-2 variants, including KP.3.1.1 and LB.1. The CDC notes KP.3.1.1 is the only major variant increasing nationally. Data has been submitted to the FDA for updates to the PEMGARDA™ Fact Sheet.
September 03, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's PEMGARDA™ continues to neutralize key SARS-CoV-2 variants, including KP.3.1.1, which is increasing nationally. This could enhance the product's market position and lead to FDA updates.
The ongoing neutralizing effect of PEMGARDA™ against dominant variants, especially KP.3.1.1, which is increasing nationally, suggests a strong market position for Invivyd. The submission of data to the FDA for updates indicates potential regulatory advancements, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100